# Design Therapeutics, Inc.: overview

DSGN · Nasdaq · CIK 1807120 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/dsgn.md) · [Financials](/companies/dsgn/financials.md) · [Filings](/companies/dsgn/filings.md) · [Insiders](/companies/dsgn/insiders.md)

Latest reported revenue: [$0](/filings/0001193125-26-329579.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 3, 2026 (XBRL us-gaap:Revenues, accession 0001193125-26-329579).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | [0.0](/filings/0000950170-25-065643.md) | [0.0 d](/filings/0000950170-25-105062.md) | [0.0 d](/filings/0001193125-25-266970.md) | [0.0 d](/filings/0001193125-26-098491.md) | [0.0](/filings/0001193125-26-187063.md) | [0.0 d](/filings/0001193125-26-329579.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(0.23)](/filings/0001193125-25-266970.md) | not reported | [(0.31)](/filings/0001193125-26-187063.md) | [(0.34)](/filings/0001193125-26-329579.md) | [(0.30)](/filings/0001193125-25-266970.md) | not reported | [(0.29)](/filings/0001193125-26-187063.md) | [(0.32)](/filings/0001193125-26-329579.md) |
| Free cash flow | $m | [(9.6) d](/filings/0001193125-25-266970.md) | [(9.9) d](/filings/0001193125-26-098491.md) | [(16.9)](/filings/0001193125-26-187063.md) | [(14.5) d](/filings/0001193125-26-329579.md) | [(11.2) d](/filings/0001193125-25-266970.md) | [(12.0) d](/filings/0001193125-26-098491.md) | [(16.4)](/filings/0001193125-26-187063.md) | [(15.5) d](/filings/0001193125-26-329579.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | [0.0](/filings/0000950170-25-035910.md) | [0.0](/filings/0001193125-26-098491.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(0.77)](/filings/0000950170-23-007869.md) | [(1.14)](/filings/0000950170-24-033492.md) | [(1.19)](/filings/0000950170-25-035910.md) | [(0.88)](/filings/0001193125-26-098491.md) | [(1.22)](/filings/0001193125-26-098491.md) |
| Free cash flow | $m | [(30.9)](/filings/0000950170-23-007869.md) | [(52.2)](/filings/0000950170-24-033492.md) | [(58.8)](/filings/0000950170-25-035910.md) | [(43.4)](/filings/0001193125-26-098491.md) | [(54.6)](/filings/0001193125-26-098491.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/dsgn/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [SR One Capital Management, LP](/funds/1910264.md) | 2026-06-30 | $94.4m | 6,526,476 |  | Unchanged |
| [Logos Global Management LP](/funds/1792126.md) | 2026-06-30 | $43.4m | 3,000,000 |  | Added +1,050,000 |
| [BAKER BROS. ADVISORS LP](/funds/1263508.md) | 2026-06-30 | $38.8m | 2,678,430 |  | Added +92,452 |
| [Driehaus Capital Management LLC](/funds/938206.md) | 2026-06-30 | $38.5m | 2,661,115 |  | Added +916,128 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $38.5m | 2,660,024 |  | Added +526,260 |
| [Point72 Asset Management, L.P.](/funds/1603466.md) | 2026-06-30 | $34.2m | 2,366,453 |  | Reduced −356,301 |
| [Trails Edge Capital Partners, LP](/funds/2077247.md) | 2026-06-30 | $29.0m | 2,001,282 |  | Added +1,149,269 |
| [Frazier Life Sciences Management, L.P.](/funds/1892134.md) | 2026-06-30 | $26.2m | 1,809,854 |  | New +1,809,854 |
| [Vivo Capital, LLC](/funds/1674712.md) | 2026-06-30 | $23.3m | 1,612,903 |  | Unchanged |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $22.7m | 1,571,022 |  | Added +221,172 |

## Recent filings

[All 262 filings](/companies/dsgn/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-03 | 08:07 ET | [10-Q](/filings/0001193125-26-329579.md) | Quarterly report, period 2026-06-30 | 0001193125-26-329579 |
| 2026-08-03 | 08:03 ET | [8-K](/filings/0001193125-26-329570.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-329570 |
| 2026-06-11 | 16:05 ET | [8-K](/filings/0001193125-26-267485.md) | 5.07 Shareholder vote results | 0001193125-26-267485 |
| 2026-05-18 | 07:15 ET | [8-K](/filings/0001193125-26-227875.md) | 8.01 Other events | 0001193125-26-227875 |
| 2026-04-28 | 16:13 ET | [10-Q](/filings/0001193125-26-187063.md) | Quarterly report, period 2026-03-31 | 0001193125-26-187063 |
| 2026-04-28 | 16:09 ET | [8-K](/filings/0001193125-26-187012.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure | 0001193125-26-187012 |
| 2026-04-23 | 16:06 ET | [DEF 14A](/filings/0001193125-26-173678.md) | Proxy statement, period 2026-04-23 | 0001193125-26-173678 |
| 2026-04-01 | 16:03 ET | [8-K](/filings/0001193125-26-137861.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-137861 |
| 2026-03-11 | 21:28 ET | [SCHEDULE 13D/A](/filings/0001072613-26-000257.md) | Ownership report, active investor, amended | 0001072613-26-000257 |
| 2026-03-09 | 16:08 ET | [10-K](/filings/0001193125-26-098491.md) | Annual report, period 2025-12-31 | 0001193125-26-098491 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-098491.md), filed Mar 9, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/05d2c456-43aa-4f04-9266-ca8b69225b92)

## About the filer

- CIK: 1807120
- Tickers: DSGN
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.